Ligufalimab

Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity[1].

Product Specifications

CAS Number

[2428381-55-7]

Product Name Alternative

AK 117

UNSPSC

12352203

Target

CD47; Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ligufalimab.html

Purity

98.81

Solubility

10 mM in DMSO

Smiles

[Ligufalimab]

Molecular Weight

(144.58 kDa)

References & Citations

[1]Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. J Immunother Cancer. 2022 Nov;10 (11) :e005517.